Author

Rémi Tellier

Centre Hospitalier Universitaire de LilleORCID 0000-0002-5709-3995Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:clustering· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Agathe LaratteiD· 2 shared Alexis Benjamin CortotiD· 2 shared Audrey VinchentiD· 2 shared Céline VillenetiD· 2 shared Clotilde DescarpentriesiD· 2 shared David TulasneiD· 2 shared Jean‐Pascal MenebooiD· 2 shared Marie FernandesiD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Agathe LaratteORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 10, 2025

Oncogenic mutations convert MET from a pro-apoptotic tumor suppressor to an oncogenic driver

Rémi Tellier, Marie Fernandes, Audrey Vinchent…·David Tulasne

The paper shows that MET exon 14 skipping mutations eliminate the pro-apoptotic function of MET, converting it from a tumor suppressor to an oncogenic driver in lung adenocarcinomas.

DOI 10.1101/2025.11.10.687614

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologyMolecular OncologyPeer-reviewedFeb 20, 2025

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

Célia Guérin, Audrey Vinchent, Marie Fernandes…·David Tulasne

This paper identifies N-lobe MET mutations in HPRCC that require ligand stimulation for activation, unlike kinase domain mutations, and shows their sensitivity to MET inhibitors.

8 citations

humanproteomics

𝕏 PostBluesky